Inc. AMAG. Shares have lost about 6.6% in the past month, underperforming the market. Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors …
Five analysts surveyed by Zacks expected $166.8 million. AMAG Pharmaceuticals shares have fallen 62 percent since the beginning of the year. The stock has decreased 50 percent in the last 12 months. This story was generated by …
Yahoo!3mon
Jones has also experienced a tough 2017 with his fund's position in AMAG Pharmaceuticals. The biotech's stock is down around 35% so far this year. AMAG's problems started in January when the company announced its fourth-quarter …
One such stock that you may want to consider dropping is AMAG Pharmaceuticals, Inc. AMAG, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current …
have a significant and adverse impact on AMAG’s stock price. AMAG cautions you not to place undue reliance on any …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
Aug 31 (Reuters) - Amag Pharmaceuticals Inc: * Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia * Amag Pharmaceuticals …